Resveratrol Reduces C-reactive Protein and Cholesterol in Schizophrenia
Karine Zortea *
Schizophrenia Program, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil and Programa de Pós-Graduação em Psiquiatria e Ciências do Comportamento, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
Viviane Carvalho Franco
Schizophrenia Program, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil and Programa de Pós-Graduação em Psiquiatria e Ciências do Comportamento, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
Lenise Petter Francesconi
Schizophrenia Program, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil and Programa de Pós-Graduação em Psiquiatria e Ciências do Comportamento, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
Paulo Belmonte-de-Abreu
Schizophrenia Program, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil and Programa de Pós-Graduação em Psiquiatria e Ciências do Comportamento, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
*Author to whom correspondence should be addressed.
Abstract
Patients with schizophrenia (SZ) are generally found with overweight and obesity and several metabolic disorders. Additionally these patients have less life expectancy, with cardiovascular disease (CVD) the main cause of increased mortality in these patients. This is a case-report study of a male, 46 years old, with Diagnosis of SZ following a 1-month resveratrol supplementation program. In summary, we observed association of resveratrol supplementation (200 mg/day) with reduced C-reactive protein (CRP), and reduced cholesterol and triglycerides. The benefits included the improvement in Framingham score and mean reduction of 3% of risk of a heart attack over the next 10 years.
Keywords: Schizophrenia, Cardiovascular Diseases, Inflammation, Resveratrol